AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05973045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Hysteroscopy 37 Centigrade Degree
Description: Operative hysteroscopy will be performed using a heated distention medium.
Study NCT04868357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
Study NCT04868357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
Study NCT04767087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: 0.5 gm/Kg/day honey
Study NCT04767087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nigella sativa seed
Description: 40 mg/Kg/day
Study NCT04767087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty capsule with sugar water
Study NCT04984187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity laser plus exercise
Description: high intensity laser plus exercise
Study NCT04984187 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: high intensity laser only
Description: high intensity laser only
Study NCT04984187 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: exercise only
Study NCT06222229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention.
Study NCT06222229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention.
Study NCT06222229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional bandage
Description: The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended
Study NCT04629339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB086550
Description: INCB086550 will be administered orally twice a day.
Study NCT06503887 — intervention group
Intervention type: OTHER
Intervention: Stool sample collection
Description: Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis
Study NCT06679166 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05376462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantra System with the QStat Cartridge
Description: Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
Study NCT05376462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laboratory Tests
Description: Laboratory tests that provide information about a patient's coagulation status.
Study NCT04635189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
Study NCT04635189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
Study NCT04635189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
Study NCT04635189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
Study NCT04635189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab
Study NCT05061706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily.
Study NCT05061706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily.
Study NCT05295056 — intervention group
Intervention type: DEVICE
Intervention: AFGen1 Device Wear Test
Description: Participant wears the device for 7 days
Study NCT05295056 — intervention group
Intervention type: DEVICE
Intervention: AFGen 1 Device Single Use
Description: Participant wears the device in conjunction with a standard ECG
Study NCT04940767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.
Study NCT04940767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amzeeq 4% Topical Foam
Description: AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
Study NCT06556290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free and casein free diet
Description: Parents will be advised for three months to ensure that children with autism spectrum disorder follow a casein-free and gluten-free diet during this period.
Study NCT05754463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of plyometric training on balance and proprioception in athletes in different branches
Description: Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
Study NCT05754463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The effect of plyometric training on balance and proprioception in athletes in different branches
Description: Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
Study NCT05970640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3006337
Description: BI 3006337
Study NCT05970640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 3006337
Description: Placebo matching BI 3006337
Study NCT05703841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
Study NCT05470686 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood gas via arterial catheter
Description: Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
Study NCT05382130 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test all
Description: In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results.
Study NCT05311423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra
Description: Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
Study NCT05755269 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05755269 — intervention group
Intervention type: PROCEDURE
Intervention: Genotyping
Description: Undergo genotyping
Study NCT05755269 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study NCT05516121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLT-015
Description: 100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
Study NCT06334458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups
Description: Early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile
Study NCT05515575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
Study NCT06643260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piclidenoson
Description: Piclidenoson is a selective A3AR agonist, supplied as tablets.
Study NCT06643260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive control
Study NCT06644092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigation of the Effectiveness of Physiotherapy and Rehabilitation After Osteochondral Allograft Transplantation Operation
Description: The treatment protocol to be applied to the patients after surgery was determined. The protocol includes; cold application, game ready device application, CPM device application, patellar mobilization, soft tissue mobilization application, TENS, conventional TENS and NMES application, ultrasound application, stretching exercises, strengthening exercises, mobilization exercises, balance and proprioception exercises, walking training and kinesio taping.
Study NCT06183021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital pulp cryotherapy
Description: Shaved ice made from sterile distilled water will be applied around the treated tooth especially in contact with amputated pulp tissue until totally dissolves.
Study NCT06183021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracanal cryotherapy
Description: After mechanical preparation, a 5-minute final irrigation with 20 mL cold saline (2.5 Centigrade degrees) will be applied using a negative pressure irrigation technique per canal.
Study NCT04630769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP FT516
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation
Study NCT04630769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy
Study NCT04630769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
Study NCT06239428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-TREAT
Description: A 12-session internet-based cognitive behavioral intervention for Danish adolescents and adults with Other Specified Feeding or Eating Disorders.
Study NCT06239428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: A 12-week waitlist with access to online mindfulness material.
Study NCT06367361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole
Description: Human studies have shown that doses up to 60 mg/kg (approximately 3.6 g for a 60-kg human, which is considered the average weight of an adult in developing countries) are safe and that repeated doses of 15 mg/kg (approximately 900 mg for a 60-kg human) daily for 5 days are safe. A single dose of OXF results in significant plasma drug concentrations that reach a Cmax plateau after doses of 15 mg/kg.75 The dose to be studied in this trial is 20 mg/kg (1200 mg maximum dose), a dose only slightly higher than that achieving a Cmax plateau. This dose was conservatively selected to account for interindividual variation in plasma levels and deemed well tolerated and safe based on laboratory and ECG evaluations.
Study NCT05386173 — intervention group
Intervention type: PROCEDURE
Intervention: Fetal aortic balloon dilatation
Description: Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
Study NCT05044468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Given via injection
Study NCT05044468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Given via injection
Study NCT05044468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06367361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclabendazole
Description: The standard of care for the treatment of fascioliasis according to the same guidelines is two 10 mg/kg doses of TCBZ 24 hours apart administered with a fat containing meal. The subjects in one of the arms of the study will receive this treatment as the standard of care. Subjects from any of the arms that fail to achieve parasitological cure will receive rescue treatment off the study with two doses of TCBZ as recommended by the Peruvian guidelines.
Study NCT05044468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06037811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.
Study NCT06037811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone as per standard of care.
Study NCT05697380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Bridge™
Description: Evidence-based speech language therapy treatment will be compared and contrasted.
Study NCT05486299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted single-port general surgery
Description: Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
Study NCT06357156 — intervention group
Intervention type: RADIATION
Intervention: CBCT
Description: The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.
Study NCT06424691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailored Recommendations
Description: Based on the microbiome analysis, participants will receive personalized action plans. These plans include dietary, lifestyle, and supplemental suggestions to improve their infant's gut health.
Study NCT06424691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consult Call
Description: Participants will have seven consult calls with a Gut Health Coach over the course of the study. These calls will provide guidance on the gut health reports, action plans, and any questions or concerns parents may have.
Study NCT06424691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email Series
Description: Parents will receive a series of educational emails covering topics such as the importance of gut health, breastfeeding benefits, the impact of C-section delivery on the microbiome, and tips for introducing solid foods.
Study NCT05777824 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: anti-PD-1 or PD-L1 antibody
Description: immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
Study NCT05849844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanoseal
Description: All subjects will receive the Tympanoseal device that will be placed during a surgical procedure
Study NCT05896202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taVNS Video
Description: One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
Study NCT05896202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.
Study NCT05896202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.